Editas Medicine Reports Inducement Grant to New Chief Financial Officer
18. Mai 2023 16:30 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., May 18, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the grant of an inducement award to the Company’s...
Editas Medicine Announces Appointment of Erick J. Lucera as Chief Financial Officer
16. Mai 2023 16:30 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., May 16, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Erick J. Lucera as Executive...
Editas Medicine to Present Clinical Data from the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease at the EHA 2023 Congress
11. Mai 2023 10:32 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that a scientific abstract detailing safety and...
Editas Medicine Announces First Quarter 2023 Results and Business Updates
05. Mai 2023 07:00 ET
|
Editas Medicine, Inc.
Company to provide a clinical update on the EDIT-301 Phase 1/2 RUBY trial for SCD in June at the European Hematology Association Congress (EHA) and in a Company-sponsored webinar On track to dose...
Editas Medicine Announces Publication in Nature Biotechnology of Comprehensive SLEEK Gene Editing Technology Data
01. Mai 2023 16:01 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., May 01, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that the journal Nature Biotechnology published the...
Editas Medicine Announces First Quarter 2023 Results Conference Call and Upcoming Investor Events
01. Mai 2023 06:45 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., May 01, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a conference call and webcast...
Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Sickle Cell Disease
27. April 2023 09:00 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that the U.S. Food and Drug Administration (FDA)...
Editas Medicine Strengthens Board of Directors with Appointment of New Chair and New Director
13. April 2023 09:00 ET
|
Editas Medicine, Inc.
Emma Reeve to support Editas’ evolution in new role as Chair of the Board Elliott Levy, M.D., joins Board as an Independent Director CAMBRIDGE, Mass., April 13, 2023 (GLOBE NEWSWIRE)...
Editas Medicine Strengthens Executive Leadership Team with Appointment of Linea Aspesi as Chief People Officer
08. März 2023 09:00 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Linea Aspesi as the Company’s...
Editas Medicine Announces Fourth Quarter and Full Year 2022 Results and Business Updates
22. Februar 2023 06:15 ET
|
Editas Medicine, Inc.
Commenced parallel patient dosing in the EDIT-301 RUBY trial for SCD, following clinical proof-of-concept demonstrated last quarter On track to provide clinical update for RUBY trial by mid-2023 and...